EQL Pharma

The transaction has taken place in a block entry outside the market at a price of SEK 37.5 per share in EQL Pharma. Before the transaction, Fårö Capital owned 8,727,348 shares, corresponding to approximately 30% of the votes and capital in EQL Pharma. After the transaction, Fårö Capital owns approximately 29 percent of the votes and capital in EQL Pharma.

The sale was prompted by the fact that a number of the major Swedish investment banks considered that the proportion of institutional ownership and the liquidity in the share needed to increase.